BridgeBio Pharma (NASDAQ:BBIO) Stock Purchase Revealed by Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO). In a filing disclosed on November 10th, the Representative disclosed that they had bought between $1,001 and $15,000 in BridgeBio Pharma stock on October 27th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 11/2/2026.
• Purchased $1,001 – $15,000 in shares of argenex (NASDAQ:ARGX) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Illumina (NASDAQ:ILMN) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Revvity (NYSE:RVTY) on 10/27/2026.
• Sold $15,001 – $50,000 in shares of PTC (NASDAQ:PTC) on 10/27/2026.
• Purchased $1,001 – $15,000 in shares of MACOM Technology Solutions (NASDAQ:MTSI) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Micron Solutions (OTCMKTS:MICR) on 10/21/2026.
• Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/21/2026.
• Purchased $1,001 – $15,000 in shares of ServiceNow (NYSE:NOW) on 10/21/2026.
• Purchased $1,001 – $15,000 in shares of Moderna (NASDAQ:MRNA) on 10/20/2026.

BridgeBio Pharma Trading Down 1.7%

Shares of NASDAQ BBIO traded down $1.37 during trading on Thursday, reaching $78.17. The company had a trading volume of 1,804,089 shares, compared to its average volume of 3,105,492. BridgeBio Pharma, Inc. has a 12-month low of $62.50 and a 12-month high of $93.42. The business’s 50-day moving average is $69.92 and its 200 day moving average is $72.79.

BridgeBio Pharma (NASDAQ:BBIO) last posted its quarterly earnings results on Thursday, October 29th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.12. The company had revenue of $353.17 million during the quarter, compared to analysts’ expectations of $293.47 million. BridgeBio Pharma’s revenue for the quarter was up 192.6% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.95) EPS. As a group, equities analysts forecast that BridgeBio Pharma, Inc. will post -2.55 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently commented on BBIO shares. Mizuho increased their price target on shares of BridgeBio Pharma from $96.00 to $110.00 and gave the company an “outperform” rating in a report on Tuesday, September 1st. HC Wainwright reaffirmed a “buy” rating on shares of BridgeBio Pharma in a research report on Tuesday, October 6th. Piper Sandler boosted their target price on shares of BridgeBio Pharma from $115.00 to $120.00 and gave the company an “overweight” rating in a research note on Monday, October 19th. Cantor Fitzgerald reissued an “overweight” rating on shares of BridgeBio Pharma in a report on Monday, October 5th. Finally, JPMorgan Chase & Co. upped their price target on shares of BridgeBio Pharma from $100.00 to $111.00 and gave the company an “overweight” rating in a research report on Wednesday, August 12th. Nineteen investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $104.26.

Insiders Place Their Bets

In related news, CEO Neil Kumar sold 10,000 shares of the company’s stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $69.08, for a total value of $690,800.00. Following the transaction, the chief executive officer directly owned 495,686 shares of the company’s stock, valued at $34,241,988.88. This represents a 1.98% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Maricel Apuli sold 2,000 shares of the company’s stock in a transaction on Friday, October 30th. The shares were sold at an average price of $72.85, for a total value of $145,700.00. Following the completion of the transaction, the chief accounting officer directly owned 120,687 shares in the company, valued at approximately $8,792,047.95. The trade was a 1.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 56,980 shares of company stock worth $4,563,699 over the last three months. Corporate insiders own 14.23% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Meeder Advisory Services Inc. bought a new position in shares of BridgeBio Pharma during the 3rd quarter valued at approximately $239,000. First Trust Advisors LP increased its stake in shares of BridgeBio Pharma by 52.2% during the third quarter. First Trust Advisors LP now owns 376,934 shares of the company’s stock valued at $24,802,000 after buying an additional 129,196 shares during the period. Landscape Capital Management L.L.C. purchased a new position in BridgeBio Pharma during the third quarter valued at approximately $605,000. Teachers Retirement System of The State of Kentucky boosted its holdings in shares of BridgeBio Pharma by 322.1% in the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 77,644 shares of the company’s stock valued at $5,109,000 after buying an additional 59,248 shares in the last quarter. Finally, HighTower Advisors LLC lifted its holdings in shares of BridgeBio Pharma by 0.9% during the 3rd quarter. HighTower Advisors LLC now owns 46,263 shares of the company’s stock valued at $3,044,000 after purchasing an additional 432 shares during the last quarter. Institutional investors own 99.85% of the company’s stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

BridgeBio Pharma Company Profile

BridgeBio Pharma is a biopharmaceutical company that discovers, develops and commercializes medicines for genetic diseases and cancers. Founded in 2015, the company advances programs through a network of research and development subsidiaries focused on specific conditions and therapeutic areas. Its products include Attruby (acoramidis), an FDA-approved treatment for adults with transthyretin amyloid cardiomyopathy. BridgeBio also develops a pipeline of investigational therapies aimed at diseases with well-understood genetic causes, including rare and inherited conditions.